**New Biotech Firm Raises $300 Million with Focus on Heart Disease**
In a bold move that has sent shockwaves through the biotech industry, MyoKardia’s former CEO, Tassos Gianakakos, has announced the launch of a new heart disease company, Kardigan. The startup has successfully raised an impressive $300 million in Series A funding, setting the stage for groundbreaking advancements in targeted drugs for heart disease treatment.
**A Passion for Cardiology**
Following Bristol Myers Squibb’s acquisition of MyoKardia for a staggering $13 billion in 2020, Gianakakos found himself at a crossroads. His deep-rooted passion for cardiology clashed with the sudden loss of his role within the company he helped build. Undeterred by this setback, Gianakakos and his executive team wasted no time in laying the groundwork for Kardigan, a biotech firm that aims to revolutionize heart disease treatment.
**Venture Capital Firms Backing Innovation**
The $300 million funding round, spearheaded by three renowned venture capital firms – Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage – highlights the industry’s confidence in Kardigan’s potential for success. With bases in South San Francisco and Princeton, N.J., Kardigan boasts a team of approximately 60 dedicated employees, poised to drive innovation in the realm of cardiology.
**A New Chapter in Cardiology**
Reflecting on the genesis of Kardigan, Gianakakos shared, “I started thinking about this pretty much the day after BMS bought MyoKardia, because I was, I was sort of shown the door. I mean that in a positive and affectionate way.” This candid admission underscores his unwavering commitment to advancing cardiovascular care, underscoring the personal and professional stakes at play in the biotech landscape.
**Embracing Innovation in Healthcare**
As the healthcare industry continues to evolve rapidly, Kardigan’s emergence signals a promising era of innovation in heart disease treatment. With a seasoned team, substantial funding, and a clear vision for the future, Kardigan is poised to make a lasting impact on the lives of patients battling heart disease. Stay tuned as this transformative biotech firm paves the way for a healthier tomorrow.
Matthew Herper, a seasoned journalist covering medical innovation, encapsulates the essence of Kardigan’s journey – a story of passion, resilience, and relentless pursuit of excellence in healthcare.
